The Effect of Oxytocin on Face Perception

July 1, 2015 updated by: Ilan Shelef, Soroka University Medical Center

The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia

The purpose of this study is to determine whether oxytocin affect face perception

Study Overview

Status

Suspended

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Beer Sheva, Israel
        • Soroka Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • normal or corrected to normal vision

Exclusion Criteria:

  • minors
  • pregnancy (according to a pregnancy test taken by subjects prior to participation)
  • a history of asthma or nasal polyps
  • cardiac disorders
  • hyponatremia
  • acute or chronic renal insufficiency
  • liver cirrhosis
  • neurological disease
  • other chronic disease
  • dementia, or lack of judgment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control group
Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Drug: Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Other Names:
  • syntocinon
Drug: Placebo
Placebo will be given to control group and experimental group as well.
Experimental: congenital prosopagnosia
Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
Drug: Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Other Names:
  • syntocinon
Drug: Placebo
Placebo will be given to control group and experimental group as well.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Memory performance
Time Frame: Day 2 (24 hours after encoding)
At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.
Day 2 (24 hours after encoding)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mood measurement
Time Frame: Day 1 (after oxytocin/placebo uptake)
Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake.
Day 1 (after oxytocin/placebo uptake)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Soroka University Medical Center

Collaborators

Ben-Gurion University of the Negev

Investigators

  • Principal Investigator: Shelef Ilan, MD, Soroka University Medical Center
  • Principal Investigator: Galia Avidan, Ph.D, Ben-Gurion University of the Negev

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2013

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

December 1, 2017

Study Registration Dates

First Submitted

January 26, 2014

First Submitted That Met QC Criteria

March 17, 2014

First Posted (Estimate)

March 19, 2014

Study Record Updates

Last Update Posted (Estimate)

July 2, 2015

Last Update Submitted That Met QC Criteria

July 1, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • sor010712ctil
  • ISF, 384/10 (Other Grant/Funding Number: israeli Science Foundation)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe